Investors

Printer Friendly Version View printer-friendly version
« Back
BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 20, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held on January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.

Logo - hi-res

10th Annual Biotech Showcase Presentation Details

Date:

Monday, January 8, 2018

Time:

4:00pm Pacific Time

Location:

Hilton San Francisco Union Square, Yosemite B

Webcast:

https://goo.gl/pvpJbC

Meetings
BrainStorm senior management will also be hosting institutional investor and partnering meetings at the Biotech Showcase conference or through the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with BrainStorm Cell Therapeutics, investors can reach out through the Biotech Showcase one-on-one partnering system (https://goo.gl/a1XZB3) or  register on the online system managed by the Company's US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at Access@LifeSciAdvisors.com.

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to approximately 70 patients with ALS in clinical trials conducted in the United States and Israel.  In a randomized, double blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn® compared with placebo. For more information, visit the company's website at www.brainstorm-cell.com.

CONTACTS
Corporate:
Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: 646-666-3188
uri@brainstorm-cell.com

Investors:
Michael Rice
LifeSci Advisors LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com

Media:
Matt Middleman, M.D.
LifeSci Public Relations, LLC
Phone: 646-627-8384
matt@lifescipublicrelations.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-to-present-at-the-10th-annual-biotech-showcase-300573776.html

SOURCE BrainStorm Cell Therapeutics Inc.